Zydus receives final approval from the USFDA for Ranolazine Extended-Release Tablets

Zydus receives final approval from the USFDA for Ranolazine Extended-Release Tablets Ahmedabad, 21 August, 2019 Zydus Cadila has received the final approval from the USFDA to market Ranolazine Extended-Release Tablets (US RLD - Ranexa ®), 500 mg and 1,000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group’s formulations manufacturing facility at Baddi. The group now has 271 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗